Ellis G, Ferguson M, Yamanaka E, Livingston R B, Gown A M
Department of Medicine, University of Washington, Seattle 98195.
Cancer. 1989 Jun 15;63(12):2509-14. doi: 10.1002/1097-0142(19890615)63:12<2509::aid-cncr2820631225>3.0.co;2-k.
Metastases develop in 30% to 40% of patients with operable breast cancer. Investigators have reported on the detection of occult micrometastases in bone marrow using an antibody to epithelial membrane antigen (EMA) and have since reported prognostic significance for these antibody-detected cells. In this study, two anti-cytokeratin monoclonal antibodies (35 beta H11 and 34 beta E12) were used to examine bone marrow specimens from patients with breast cancer. The technique was first studied in a test system in which human or monkey bone marrow was seeded with MCF-7 cells, and was determined to be sensitive enough to detect fewer than one cancer cell in 10(4) hematopoietic cells. An immunoglucose oxidase method was used for patient specimen antibody localization and was found to be free of false-positive staining. Marrow specimens from 25 patients with breast cancer of various stages were examined. No correlation with disease stage was observed. We conclude that the technique is feasible, but prognostic import remains to be determined.
30%至40%的可手术乳腺癌患者会发生转移。研究人员报告了使用抗上皮膜抗原（EMA）抗体检测骨髓中隐匿性微转移的情况，此后又报告了这些抗体检测到的细胞的预后意义。在本研究中，使用两种抗细胞角蛋白单克隆抗体（35βH11和34βE12）检查乳腺癌患者的骨髓标本。该技术首先在一个测试系统中进行研究，在该系统中用人或猴的骨髓接种MCF-7细胞，结果确定该技术足够灵敏，能够在10⁴个造血细胞中检测到少于一个癌细胞。采用免疫葡萄糖氧化酶方法对患者标本进行抗体定位，发现无假阳性染色。检查了25例不同分期乳腺癌患者的骨髓标本。未观察到与疾病分期的相关性。我们得出结论，该技术是可行的，但预后意义仍有待确定。
